Login
Create Account

Powerpack

Unlock full stockrow access for only $7.9/month and boost yourself as an investor.

Watchlist

Keep track of companies that you follow and research.

10 Years of Data

Full access to our data with predictions and indicators that we calculate daily.

Screener

Full access to our screener with tons of custom values and customizable email notifications.

XLS Exports

Excel export of financials and screeners you define and save.

MEDIFAST INC MED

Consumer Cyclical — Personal Services
Dividend Champion (5y) Insider Buys (last 12m)
Growth Flags show if company had growth for consecutive years ,
Insider Buys alert about insiders buying in the last 12 month

We limit data available in the Overview Report for users who do not have Powerpack

Get access to target analyst prices, predictions, compound annual growth rates and more than four years of historical data.
Register an account and get your Powerpack now or Login

Insider Decisions

Total buys
1.67
in millions of $
Nov 25 Feb 26 May 26 Aug 26
Buy — — — — — 1 — 1 — — 3 —
Sell — — — — — — — — — — — —
Insider Ownership
5.79%

Capital & Financial Ratios

Market Cap
133.72
Revenue
316.93
Net Income
(25.60)
Free Cash Flow
7.65
Net Debt
(169.82)
Current Ratio
4.86
Debt/Equity
0.00
P/E ratio
0.00
P/S ratio
0.41
P/B ratio
0.67
Past 5Y EPS Growth
(50.52%)
This Y EPS Growth
(91.67%)
Next Y EPS Growth
75.65%
Next 5Y EPS Growth
20.00%
in millions of $

Dividends

Payout Ratio
0.54
Annual Dividend Rate
6.60
Annual Dividend Yield
9.05%
total individual payouts
2024 ‡‡‡‡
2023 4.95
—
—
—
2022 6.56
—
—
—
—
2021 5.68
—
—
—
—
2020 4.52
—
—
—
—
2019 3.38
—
—
—
—
2018 2.19
—
—
—
—
2017 1.44
—
—
—
—
2016 1.07
—
—
—
—
predictions in italic, special payouts not included in total or ratios

Assets vs Liabilities

2023 2024 2025 Q'26
Cash 150.04 162.34 167.27 169.82
Receivables — — — 5.26
Inventory 54.59 42.42 20.23 21.18
Other — — — —
224.03 214.40 201.68 202.03
2023 2024 2025 Q'26
Payables 86.42 56.49 38.36 36.41
ST’ Debt — — — —
Other — — — —
92.30 64.16 42.96 41.56
in millions of $

Compound Annual Growth

10y 5y 3y
Sales ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡
Cash Flow ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡
Earnings ‡‡‡ ‡‡‡ ‡‡‡
Book Value ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡

Revenue

Mar Jun Sep Dec Year
’26 76.04 76.38 — —
—
’25 115.73 105.56 89.41 75.10
385.79
’24 174.74 168.56 140.16 119.00
602.46
’23 348.98 296.19 235.87 191.01
1,072.05
’22 417.60 453.33 390.40 337.25
1,598.58
’21 340.67 394.19 413.40 377.83
1,526.09
’20 178.46 220.00 271.47 264.91
934.84
in millions of $

Operating Cash Flow

Mar Jun Sep Dec Year
’26 0.26 1.70 — —
—
’25 3.41 (3.38) 12.11 (5.28)
6.86
’24 7.28 13.07 9.07 (4.95)
24.48
’23 64.06 43.15 29.93 10.52
147.66
’22 43.67 43.76 55.40 51.74
194.57
’21 65.33 20.88 15.80 (7.46)
94.55
’20 26.74 57.52 41.11 19.83
145.20
in millions of $

Free Cash Flow

Mar Jun Sep Dec Year
’26 2.80 0.73 — —
—
’25 1.88 (4.76) 10.75 (6.63)
1.25
’24 5.44 11.13 7.68 (7.23)
17.02
’23 61.94 41.40 28.25 9.58
141.17
’22 40.66 40.92 53.63 42.68
177.89
’21 60.73 13.28 5.41 (19.08)
60.34
’20 26.44 57.23 37.85 17.79
139.31
in millions of $

EPS

Mar Jun Sep Dec Year
’26 (0.19) (0.28) — —
—
’25 (0.07) 0.22 (0.21) (1.65)
(1.70)
’24 0.76 (0.75) 0.10 0.07
0.19
’23 3.67 2.77 2.12 0.55
9.10
’22 3.59 3.42 3.27 2.41
12.73
’21 3.46 3.96 3.56 2.91
13.89
’20 1.56 1.86 2.91 2.36
8.68

Target Price Range

High
‡‡‡‡‡
‡‡‡‡
Average
‡‡‡‡‡
‡‡‡‡
Low
‡‡‡‡‡
‡‡‡‡

Recommendation Rating

3
1
Buy
2
3
Hold
4
5
Sell
2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028
‡‡‡‡‡ ‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 96.00 61.94 16.70 10.36 — — —
Low Price
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 222.00 131.42 70.58 17.84 — — —
High Price
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 874 634 504 380 — — —
Employees
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 1.83 1.69 1.20 1.02 — — —
Revenue/Emp
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 1,598.58 1,072.05 602.46 385.79 ‡‡‡‡‡ ‡‡‡‡‡ —
Revenue
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 71.34% 72.37% 73.80% 71.33% — — —
Gross Margin
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 184.06 128.80 3.79 (5.64) — — —
EBT
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 11.51% 12.01% 0.63% (1.46%) ‡‡‡ ‡‡‡ —
EBT Margin
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 143.57 99.42 2.09 (18.67) ‡‡‡‡‡ ‡‡‡‡‡ —
Net Income
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 10.99 12.94 11.91 13.57 — — —
Depreciation
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 142.79 98.50 55.12 35.13 ‡‡‡‡‡ ‡‡‡‡‡ —
Revenue/Sh
‡‡‡‡ ‡‡‡‡ ‡‡‡‡ ‡‡‡‡ ‡‡‡‡ ‡‡‡‡‡ 12.82 9.13 0.19 (1.70) ‡‡‡‡‡ ‡‡‡‡‡ —
Earnings/Sh
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 17.38 13.57 2.24 0.63 — — —
Cash Flow/Sh
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (1.49) (0.60) (0.68) (0.51) ‡‡‡ ‡‡‡ —
Capex/Sh
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 15.89 12.97 1.56 0.11 — — —
Free CF/Sh
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 13.85 18.51 19.22 18.11 — — —
Book Value/Sh
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 11.20 10.88 10.93 10.98 ‡‡‡‡‡ ‡‡‡‡‡ —
Shares
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 9.00 7.69 97.89 0.00 ‡‡‡‡‡ ‡‡‡‡‡ —
PE Ratio
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 0.81 0.71 0.32 0.30 ‡‡‡ ‡‡‡ —
PS Ratio
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 8.31 3.79 0.92 0.59 ‡‡‡ ‡‡‡ —
PB Ratio
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 0.77 0.59 0.08 (0.09) ‡‡‡‡ ‡‡‡‡ —
EV/Sales
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 8.13 5.57 (4.75) 1.28 — — —
EV/FCF
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 194.57 147.66 24.48 6.86 ‡‡‡ ‡‡‡ —
Op' Cash Flow
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (16.68) (6.48) (7.45) (5.61) ‡‡‡‡‡ — —
Capex
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 177.89 141.17 17.02 1.25 — — —
FCF
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 81.89 131.73 150.24 158.72 — — —
Working Cap'
— — — ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 26.05 — — — — — —
Total Debt
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (61.64) (150.04) (162.34) (167.27) — — —
Net Debt
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 155.04 201.48 210.11 198.92 — — —
Sh' Equity
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 40.18% 31.76% 0.70% (7.02%) — — —
ROA
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡ ‡‡‡‡‡ 123.66% 153.58% 3.77% (28.07%) — — —
ROIC
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 80.31% 55.77% 1.02% (9.13%) — — —
ROE
predictions in italic, sparklines do not include predictions

Analyst Commentary (Summary)

Medifast Inc. (MED), the powerhouse behind Optavia’s weight-loss coaching empire, soared on pandemic demand with revenue exploding 471% to $1.6 billion in 2022, boasting sky-high efficiency and margins. But the reversal has been savage: sales cratered 62% to $602 million in 2024, with forecasts predicting another 37-44% plunge through 2026 amid the GLP-1 drug onslaught from Ozempic and Wegovy, which are gutting repeat coaching customers and exposing structural vulnerabilities.

Profitability has evaporated—from 91% ROE and fat EBT margins to razor-thin scraps, projected losses, and FCF down 90%. Valuations scream bargain (PS at 0.32, PB at 0.92), but tight correlation with the revenue cliff marks this as a classic value trap, not a steal—insiders’ token buys offer no conviction, and a cash-rich balance sheet merely delays the inevitable bleed.

Analysts peddle 39% upside, but fundamentals scream contraction, not revival. GLP-1 dominance, efficiency exhaustion, and no clear pivot spell secular decline—skip the hype unless you’re hunting lottery tickets below $10; history warns against betting on faded diet fads.

Read full commentary →

MEDIFAST INC (MED) Latest News

News by impact score

Fine-tune

9 Sep

3 , 12:10 PM
AVO posts Q3 earnings beat supported by farming strength and Calavo contribution. Q3 earnings beat signals improved results with moderate effects on performance outlook.

4 Sep

4 , 10:39 AM
Medifast advances its 3.0 strategy to restore profitable growth. Medifast's 3.0 strategy represents a major strategic move that could significantly alter company trajectory.

2 Sep

3 , 11:30 AM
Medifast (MED) shares declined 7.6% since the latest earnings release. Post-earnings price drop indicates moderate short-term pressure on stock trajectory and sentiment.

27 Aug

3 , 8:30 AM
Medifast launches the Medifast Metabolic Health Institute to advance metabolic health programs and initiatives. Institute launch supports product innovation and competitive positioning in metabolic health.

21 Aug

3 , 11:25 AM
Medifast introduces a new compensation plan to accelerate coach growth. New compensation plan targets coach expansion with moderate effects on operations and growth outlook.

12 Aug

3 , 12:35 PM
Medifast evaluates whether productivity gains among coaches can reverse recent revenue declines and restore growth momentum. Coach productivity improvements could lift operational efficiency and support revenue recovery.

11 Aug

3 , 8:21 PM
Medifast addressed top five analyst questions on Q2 results, operations, and outlook during its earnings call. Q2 earnings discussion and analyst questions provide performance details that moderately influence investor sentiment.

10 Aug

4 transcript www.fool.com, 9:48 PM
Medifast (MED) released its Q2 2026 earnings call transcript covering quarterly financial results, operational updates and forward outlook. Earnings call transcript delivers core financial metrics and guidance that materially shape MED's valuation and investor outlook.

7 Aug

4 , 2:22 PM
MEDIFAST INC considers Trilivy launch and cost cuts as potential drivers for Q4 profit turnaround. Trilivy launch and cost cuts represent major strategic moves that could significantly alter MEDIFAST INC financial trajectory and investor sentiment.

3 , 2:17 PM
MEDIFAST INC trades at low valuation while executing a high-risk turnaround that raises questions over its attractiveness as an investment. Discussion of valuation versus turnaround risk can moderately shift near-term investor sentiment and share-price trajectory for MEDIFAST INC.

4 Aug

4 transcript , 1:08 AM
Medifast Inc (MED) announced a strategic pivot to Trilivy in its Q2 2026 earnings call. Strategic pivot to Trilivy represents major move likely to alter company trajectory and investor views.

3 , 12:19 PM
Medifast posted a narrower-than-expected Q2 loss with improved coach productivity. Narrower Q2 loss and productivity gains indicate modestly better operational results that may support short-term sentiment.

3 app.moby.co, 8:30 AM
Medifast, Inc. reported Q2 2026 financial results and outlook during its earnings call. Q2 earnings and guidance directly inform near-term financial trajectory and investor views for MED.

3 Aug

3 transcript www.marketbeat.com, 8:03 PM
Medifast reported Q2 revenue, earnings, and operational metrics during its earnings call, along with updated guidance and comments on customer acquisition, product strategy, and market conditions. Quarterly earnings and guidance provide direct financial benchmarks that shape near-term valuation and sentiment but rarely shift long-term company trajectory.

3 , 5:12 PM
Medifast beats Q2 CY2026 expectations with strong results, driving a 12.8% stock increase. Quarterly earnings beat produces short-term stock movement without shifting long-term company trajectory.

3 , 4:05 PM
Medifast Inc reported financial results for the second quarter of 2026. Quarterly earnings releases provide performance data that can shift near-term stock valuation and sentiment.

29 Jul

3 , 11:33 AM
Medifast Inc. is scheduled to release its Q2 earnings, with investors advised to focus on revenue, EPS, and company guidance that may shape near-term stock movement. Quarterly earnings release can move revenue and EPS expectations and thereby affect near-term share price.

20 Jul

4 , 10:27 AM
Medifast prepares Trilivy launch that could open a new growth chapter for the company. Trilivy launch is a major product introduction positioned to significantly shift Medifast growth trajectory.

17 Jul

4 , 8:30 AM
Medifast launches Trilivy, a science-backed metabolic health system. Trilivy launch marks major strategic product introduction in core metabolic health market.

7 Jul

3 , 10:33 AM
MEDIFAST INC (MED) carries three major risks that undermine its investment case, leading to a direct recommendation of an alternative stock instead. Negative risk assessment for MEDIFAST INC is likely to pressure investor sentiment and near-term share price.

26 May

3 Business Wire, 4:05 PM
Medifast confirms appointment of Nicholas Johnson as Chief Executive Officer. CEO appointment may shift strategy and market sentiment but is unlikely to fundamentally alter company trajectory.

15 May

4 GlobeNewswire, 1:00 PM
Peer-reviewed research confirms structured meal replacement programs reduce visceral fat while preserving lean mass, validating MEDIFAST INC's (MED) core offerings. Peer-reviewed validation of product efficacy strengthens MEDIFAST's competitive positioning and market sentiment.

4 GlobeNewswire, 1:00 PM
Peer-reviewed research redefines weight loss program standards, highlighting Medifast Inc. (MED)'s programs as leaders in efficacy and innovation. Peer-reviewed validation elevates Medifast's programs, driving competitive advantage and positive investor sentiment.

5 May

3 Zacks, 1:58 PM
Medifast's Q1 loss narrowed more than expected despite a year-over-year revenue decline. Narrower-than-expected Q1 loss provides moderate positive impact on financial performance amid revenue decline.

4 May

4 www.marketbeat.com, 9:10 PM
Medifast released Q1 earnings call highlights, covering financial results, revenue guidance, operational updates, and strategic priorities for OPTAVIA brand growth amid market challenges. Q1 earnings highlights reveal financial performance and guidance that significantly shape investor expectations and stock trajectory.

4 app.moby.co, 8:25 PM
Medifast, Inc. Q1 2026 earnings call summary covers financial results, operational updates, and forward-looking guidance for the weight management company. Q1 2026 earnings disclosure includes financial metrics and strategic shifts directly influencing MED's market performance and investor outlook.

4 transcript www.fool.com, 6:14 PM
Medifast (MED) released Q1 2026 earnings call transcript detailing financial results, revenue decline, Optavia challenges, cost-cutting measures, and cautious outlook amid market shifts. Q1 2026 earnings reveal revenue drop, profitability pressures, and strategic pivots that could reshape Medifast's trajectory and investor confidence.

4 StockStory, 4:42 PM
Medifast (NYSE:MED) delivered impressive Q1 CY2026 results. Impressive quarterly earnings indicate significant positive impact on financial performance and investor sentiment.

4 Business Wire, 4:05 PM
Medifast announced first quarter 2026 financial results. Quarterly earnings announcement reveals key financial metrics that can significantly sway stock price and investor outlook.

3 Zacks, 5:50 PM
Medifast (MED) reported a Q1 loss but exceeded revenue estimates. Q1 loss highlights profitability pressures despite revenue beat, moderately affecting financial performance and investor sentiment.
© 2016–2026 stockrow.com Terms and Conditions Indicators Contact Us